Atocha Romero
Atocha Romero
Hospital Universitario Puerta de Hierro
Verified email at - Homepage
Cited by
Cited by
Association analysis identifies 65 new breast cancer risk loci
K Michailidou, S Lindström, J Dennis, J Beesley, S Hui, S Kar, A Lemaçon, ...
Nature 551 (7678), 92-94, 2017
Polygenic risk scores for prediction of breast cancer and breast cancer subtypes
N Mavaddat, K Michailidou, J Dennis, M Lush, L Fachal, A Lee, JP Tyrer, ...
The American Journal of Human Genetics 104 (1), 21-34, 2019
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ...
The Lancet Oncology 21 (11), 1413-1422, 2020
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer
TR Rebbeck, N Mitra, F Wan, OM Sinilnikova, S Healey, L McGuffog, ...
Jama 313 (13), 1347-1361, 2015
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ...
Nature genetics 49 (12), 1767-1778, 2017
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
H Zhang, TU Ahearn, J Lecarpentier, D Barnes, J Beesley, G Qi, X Jiang, ...
Nature genetics 52 (6), 572-581, 2020
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk
FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ...
PLoS genetics 9 (3), e1003212, 2013
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer
L Wu, W Shi, J Long, X Guo, K Michailidou, J Beesley, MK Bolla, XO Shu, ...
Nature genetics 50 (7), 968-978, 2018
Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial)
M Provencio, R Serna-Blasco, E Nadal, A Insa, MR García-Campelo, ...
Journal of Clinical Oncology 40 (25), 2924-2933, 2022
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
L Fachal, H Aschard, J Beesley, DR Barnes, J Allen, S Kar, KA Pooley, ...
Nature genetics 52 (1), 56-73, 2020
Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing
C Pérez-Barrios, I Nieto-Alcolado, M Torrente, C Jiménez-Sánchez, ...
Translational lung cancer research 5 (6), 665, 2016
Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer
M Provencio, E Nadal, JL González-Larriba, A Martínez-Martí, R Bernabé, ...
New England Journal of Medicine 389 (6), 504-513, 2023
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
A Cruz-Bermúdez, R Laza-Briviesca, RJ Vicente-Blanco, ...
Free Radical Biology and Medicine 135, 167-181, 2019
Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring
D Pérez-Callejo, A Romero, M Provencio, M Torrente
Translational lung cancer research 5 (5), 455, 2016
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling
A Cruz-Bermúdez, R Laza-Briviesca, RJ Vicente-Blanco, ...
Free Radical Biology and Medicine 130, 163-173, 2019
Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium
M Colombo, MJ Blok, P Whiley, M Santamarina, S Gutierrez-Enriquez, ...
Human molecular genetics 23 (14), 3666-3680, 2014
Assessment of topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization
A Romero, M Martín, MCU Cheang, JAL García-Asenjo, B Oliva, X He, ...
The American journal of pathology 178 (4), 1453-1460, 2011
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
M Martin, A Romero, MCU Cheang, JA López García-Asenjo, ...
Breast cancer research and treatment 128, 127-136, 2011
Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging
JA García-Saenz, P Ayllón, M Laig, D Acosta-Eyzaguirre, ...
BMC cancer 17, 1-8, 2017
Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients
A Romero, JA García-Sáenz, M Fuentes-Ferrer, JAL Garcia-Asenjo, ...
Annals of oncology 24 (3), 655-661, 2013
The system can't perform the operation now. Try again later.
Articles 1–20